| alogliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| alogliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.96 [0.81 1.13] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | Cardiovascular death | 0.80 [0.60 1.06] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | myocardial infarction (fatal and non fatal) | 1.07 [0.87 1.33] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | stroke (fatal and non fatal) | 0.90 [0.54 1.49] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | All cause death | 0.88 [0.70 1.10] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| alogliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All types of patients: 11 trials - Nauck - Seino - EXAMINE - Seino - Bosi - Kaku - Rosenstock - Rosenstock - Pratley - Pratley - DeFronzo
| alogliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| alogliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.96 [0.81 1.13] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | Cardiovascular death | 0.80 [0.60 1.06] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | myocardial infarction (fatal and non fatal) | 1.07 [0.87 1.33] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | stroke (fatal and non fatal) | 0.90 [0.54 1.49] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | All cause death | 0.88 [0.70 1.10] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| alogliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 1 trials - Nauck
| alogliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 1 trials - Nauck
| alogliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
